Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. [electronic resource]
Producer: 20190513Description: 1402-1409 p. digitalISSN:- 1468-1331
- Adult
- Autoantibodies
- Family
- Female
- Humans
- Immunoglobulins, Intravenous -- adverse effects
- Immunosuppressive Agents -- adverse effects
- Infant, Newborn
- Myasthenia Gravis -- drug therapy
- Neuromuscular Diseases
- Pregnancy
- Prenatal Exposure Delayed Effects -- immunology
- Pyridostigmine Bromide -- adverse effects
- Receptor Protein-Tyrosine Kinases -- immunology
- Receptors, Cholinergic -- immunology
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.